 PALO ALTO, Calif., Sept. 8, 2021 PRNewswire -- BridgeBio Pharma, Inc. Nasdaq: BBIO, a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that on September 2, 2021, the compensation committee of BridgeBios board of directors granted 29 new employees restricted stock units for an aggregate of 61,210 shares of the Companys common stock. 